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Human amyloids have been shown to interact with viruses and interfere with viral replication.
Based on this observation, we employed a synthetic biology approach in which we engineered
virus-specific amyloids against influenza A and Zika proteins. Each amyloid shares a
homologous aggregation-prone fragment with a specific viral target protein. For influenza we
demonstrate that a designer amyloid against PB2 accumulates in influenza A-infected tissue
in vivo. Moreover, this amyloid acts specifically against influenza A and its common PB2
polymorphisms, but not influenza B, which lacks the homologous fragment. Our model
amyloid demonstrates that the sequence specificity of amyloid interactions has the capacity
to tune amyloid-virus interactions while allowing for the flexibility to maintain activity on
evolutionary diverging variants.
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For decades, human amyloids were mainly studied as themajor hallmarks of protein deposition in disease, but inrecent years functional amyloids, which have been uncov-
ered in several human tissues1 and throughout all kingdoms of
life, have caused a revision of the view that amyloid structures are
intrinsically toxic or pathological. Recently, increasing evidence
supports the hypothesis that even disease-associated amyloids
may not only be pathogenic byproducts2, but that they could in
fact also possess functional benefits for instance acting as inter-
actors of human pathogens, including viruses3–6. For example, it
has been suggested that the Alzheimer’s disease (AD)-associated
peptide, amyloid beta (Aβ), may have a role in innate immunity
against herpes virus brain infections5. More specifically, Eimer
et al.5 showed that Aβ interacts with herpes glycoproteins,
thereby inducing Aβ amyloid formation. The seeding of Aβ
aggregation leads to an entrapment of the viral particles, which
results in an amyloid-driven antiviral effect. Whether reciprocally
the amyloid deposits formed as a result of such encounters with
virus have a role in the development of AD remains to be
determined, but herpes infection is a known risk factor for AD7.
Aggregation seeding, as observed for Aβ when binding to
herpes virus, is a well-described process, driven by so-called
aggregation-prone regions (APRs)8. These APRs engage into
homotypic interactions to form tightly packed intermolecular
amyloid structures, resulting in a highly sequence-specific pro-
cess9–12, but allowing the interaction between proteins sharing
highly homologous APRs. Interestingly, Aβ also shares a homolog
APR sequence with the envelope glycoprotein B4, a herpes pro-
tein for which an interaction with Aβ has already been shown5.
To study whether an amyloid that shares a homolog APR with a
certain viral protein can indeed specifically interact with this
protein and thereby interfere with viral replication, we resorted to
synthetic biology approach.
We designed two synthetic amyloids, each encoding a virus-
specific APR identified in influenza A and Zika virus (ZIKV)
proteins, respectively. We found that each amyloid interferes with
the replication of its corresponding virus, without any cross-
reactivity. For influenza A we show that our synthetic amyloid
accumulates at the site of infection and interferes with influenza
A replication in a murine infection model. The amyloid binds to
its specific viral target protein in an APR-specific manner, forcing
the protein into a nonfunctional conformation. Influenza B,
which lacks the homolog APR, is not affected by the synthetic
amyloid, highlighting the sequence specificity of this interaction.
Together, we present the design of fully synthetic amyloids, solely
based on an APR identified in a viral protein, that show specific
antiviral properties. Moreover, our results demonstrate that APR-
mediated amyloid interactions possess the same characteristics
defining bona fide functional biological interactions including
specificity and in vivo selectivity.
Results
Design of an APR-based synthetic peptide with antiviral
properties. To investigate the potential for amyloids to interact
with viruses encoding a homologous APR, we here used a syn-
thetic biology approach, using influenza A as a model virus. To
design synthetic amyloids that share a homologous APR with an
influenza A protein, we first identified all APRs in the influenza A
proteome using the statistical thermodynamics algorithm
TANGO13. We identified 40 APRs with a minimum TANGO
score of 5 in the influenza A/Puerto Rico/8/34 (A/PR8) proteome.
Synthetic peptides were designed based on those APRs using a
tandem repeat scaffold14–16: two identical APRs, supercharged
with arginine residues and linked by two amino acids (Fig. 1a,
Supplementary Table 1). The tandem design is used to stimulate
amyloid formation of our synthetic peptides, while at the same it
increases avidity of APR interactions. The charged amino acids,
on the other hand, are added to decrease the kinetics of self-
aggregation. These amyloid-prone peptides were screened for
antiviral activity against two influenza A strains: the H1N1 strain
A/PR8 and the H5N1 strain A/NIBRG-14 (Supplementary
Fig. 1a, b). Madin–Darby canine kidney (MDCK) cells were
treated with peptide at a concentration of 10 µM, 2 h prior to
infection. Following overnight incubation, the amount of newly
produced virus was determined by TCID50 titration. Overall,
peptide 12, derived from an APR identified in the cap-binding
domain of polymerase basic protein 2 (PB2), 381LIQLIVS387
(Fig. 1b), showed the most pronounced effect. Importantly, the
observed antiviral effect did not originate from aspecific cytotoxic
effects (Supplementary Fig. 1c). We selected the APR of peptide
12, 381LIQLIVS387, as the primary target APR and optimized the
peptide design to maximize antiviral activity and minimize
hemolytic activity. Different peptide variants were designed:
multiple charged amino acids and linker residues were screened
and mutations were inserted inside the APR to increase solubility
while retaining antiviral activity (Supplementary Table 2). The
antiviral effect of all peptide variants was screened by a plaque-
size reduction assay and a hemolytic activity assay was performed
on human red blood cells (Supplementary Fig. 1d, e). Taking both
parameters into account, the best scoring peptide sequence is
WDLIQLIVSDGSDLIQLIVSD, referred to as peptide 12B, in
which the target APR (381LIQLIVS387) is flanked by negatively
charged aspartate residues and an N-terminal tryptophan is
added to allow for accurate concentration determination. This
plaque-size reduction assay showed an ~80% reduction of influ-
enza A/PR8 plaque area when cells were treated with peptide 12B
(Fig. 1c, d). The antiviral effect was compared with three known
anti-influenza compounds: nucleozin, a nucleoprotein-targeting
inhibitor17, Tamiflu, a neuraminidase inhibitor, and VX-787, a
PB2 inhibitor. Of note, positively charged variants of peptide 12B
(12E–12H) show a similar antiviral effect in the plaque-size
reduction assay but were not selected for further analysis because
of the aspecific toxic effects on human red blood cells (Supple-
mentary Fig. 1e). A dose–response experiment, in which influ-
enza A/PR8-infected MDCK cells were treated with a peptide
concentration ranging from 10 nM to 75 µM, allowed to deduce
an IC50 of ~1.79 µM for peptide 12B (Fig. 1e). The cytotoxic dose
(TD50= 727 µM), derived from the hemolytic activity (Fig. 1e),
and the IC50 allowed us to estimate a therapeutic index (TI=
TD50/IC50) for peptide 12B of 406. Moreover, no aspecific toxic
effects were observed on MDCK and Human Embryonic Kidney
(HEK 293T) cells with concentrations up to 250 µM (Fig. 1f and
Supplementary Fig. 1f). Finally, we used two additional assays to
validate the antiviral effect of peptide 12B: a multicycle replication
assay and the protection against cytopathic effects (Supplemen-
tary Fig. 1g, h). Both assays confirm that peptide 12B acts as an
antiviral peptide against influenza A.
Peptide 12B shows antiviral activity in an in vivo infection
model. To determine whether peptide 12B retains its antiviral
activity in vivo, cohorts of BALB/c mice were infected with
influenza A/PR8 (2x LD50) and treated daily with buffer, 2.5 mg/
kg peptide 12B (both intravenously (i.v.)), or 25 mg/kg Tamiflu
(oral gavage). After 6 days, a small but significant reduction in
virus titers in lung homogenates was observed for 12B-treated
mice compared with buffer-treated and Tamiflu-treated mice18
(Fig. 1g). To control for any possible aspecific toxic effects of our
synthetic peptide, we performed an in vivo toxicity study. BALB/c
mice received daily i.v. injections for 2 weeks with 10 mg/kg
peptide 12B or buffer. Blood analysis and a histopathological
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evaluation of all major organs revealed no abnormalities (Sup-
plementary Fig. 2a–c and Supplementary Note 1). Biodistribution
studies with a radiolabeled variant ([68Ga]Ga-NODAGA-PEG2-
12B) in influenza A/PR8-infected BALB/c mice demonstrated a
lack of accumulation in healthy tissue, fast blood clearance, and a
high urinary elimination without kidney retention (Supplemen-
tary Fig. 2d, e). The radiolabeled peptide variant also allowed to
estimate the half-life of peptide 12B (<10 min in blood),
explaining the modest reduction in viral titers observed in vivo
(Fig. 1g) and underlines the need for more stable peptide variants
to obtain a more robust therapeutic activity. Moreover, uptake of
radiolabeled peptide 12B was approximately twofold larger in
influenza A-infected lungs compared with healthy lungs at dif-
ferent time points after peptide injection, consistent with a spe-
cific amyloid–virus interaction in vivo (Fig. 1h).
Peptide 12B organizes into amyloid-like structures. We next
performed biophysical studies of peptide 12B in vitro to verify that
it behaves as an amyloid, in accordance with the design. Dynamic
light scattering (DLS) showed that peptide 12B (100 µM) organizes
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Fig. 1 APR-based design of a synthetic peptide with antiviral activity against influenza A. a Graphical illustration of the peptide tandem design with the
target APRs capped by charged amino acids (arginine or aspartic acid) and linked by a glycine-serine or proline-proline linker. b Cap-binding domain of the
influenza A/PR8 polymerase basic protein 2 (PB2CB) (PDB= 4ENF)26,27. The target APR, 381LIQLIVS387, is surface exposed and highlighted in red. c
Plaque-size reduction assay of MDCK cells treated with cell medium, 1% DMSO, 10 µM peptide 12B, 10 µM nucleozin, 100 µM Tamiflu, or 1 µM VX-787 2 h
prior to infection with influenza A/PR8. d Quantification of the area covered by plaques in c. Data are normalized to medium-treated cells and mean ± SD is
shown (n= 4 independent experiments, statistics: one-way ANOVA with multiple comparison). e Dose-dependent effect of peptide 12B on area covered
by plaques (red curve, left axis) and on red blood cell (RBC) lysis (purple curve, right axis). For IC50: data are normalized to buffer-treated cells and the
mean ± SD is shown (n= 4 independent experiments). For toxic dose (TD50): data are normalized to buffer-treated (0% lysis) and 0.1% Triton-treated
cells (100% lysis) and the mean ± SD is shown (n= 3 independent experiments). f Dose-dependent toxicity of peptide 12B, after 24-h incubation on MDCK
cells. Data are normalized to buffer-treated (100% viability) and 0.1% Triton-treated cells (0% viability) and the mean ± SD is shown (n= 3 independent
experiments). g Viral load in the lungs of influenza A/PR8-infected mice after daily injections of either buffer, 2.5 mg/kg peptide 12B, 2.5 mg/kg peptide
12Bpro2 (all i.v.), or 25 mg/kg Tamiflu (oral gavage) for 6 consecutive days. Data are expressed as mean ± SD (n= 13 mice over six independent
experiments, statistics: one-way ANOVA with multiple comparison). h Relative concentrations (SUV) of peptide [68Ga]Ga-NODAGA-PEG2-12B in the
lungs of A/PR8-infected versus healthy mice at different time points after peptide injection. The data are expressed as mean ± SD (n= 12 mice over six
independent experiments, statistics: two-sided unpaired Student’s t test).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16721-8 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:2832 | https://doi.org/10.1038/s41467-020-16721-8 | www.nature.com/naturecommunications 3
into small structures (<50 nm) that evolve into larger aggregates
(~1 µm) within 20 h (Fig. 2a). Freshly dissolved peptide 12B already
binds the amyloid-specific dye thioflavin-T (Th-T) and the Th-T
spectra do not change significantly over time (Fig. 2b, c). The
Fourier-transform infrared (FTIR) spectrum of a freshly dissolved
peptide shows a main peak at 1624 cm−1, which is indicative of
intermolecular beta-sheet formation and is hence typically observed
for amyloid-like aggregates19 (Fig. 3d). To evaluate peptide aggre-
gate morphology, we used transmission electron microscopy
(TEM), showing amyloid-like structures of ±8–10 nm in width
(Fig. 3e). However, in contrast to typical amyloid fibers, peptide 12B
appears to organize in shorter, curved fibers, sometimes forming
annular aggregates20,21. Cryo-TEM images confirm that these
structures are present in solution and are not an artifact of
the drying or staining steps in regular TEM (Fig. 3f). Together, these
data indicate that peptide 12B organizes into small beta-sheet-
containing structures that grow into larger amyloid-like aggregates
over time. Importantly, DLS results indicate that these small oli-
gomeric structures can be stabilized by simply keeping peptide 12B
at a low concentration (10 µM), which is approximately fivefold
higher than its IC50, as described in the antiviral assays above
(Fig. 3g). Finally, these small oligomeric structures are soluble, as
shown by ultracentrifugation followed by concentration determi-
nation at different time points (Fig. 3h).
Forming amyloid is necessary but insufficient for antiviral
activity. As controls, we designed two additional peptides, in
which we maintained an identical scaffold but altered the APR
cores (Supplementary Table 3). Peptide 12Bpro2 was designed
as a control for the role of beta-strand-mediated aggregation by
introducing two proline mutations in each APR to reduce the
aggregation propensity while avoiding the introduction of
additional charged residues22. Peptide 12Bscr2 was designed as
a control for the sequence specificity of aggregation by
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Fig. 2 Peptide 12B organizes into amyloid-like structures in vitro. a Hydrodynamic radius (RH) calculated from the regularization fit of DLS data of peptide
12B (100 µM) maturation over time. b Th-T emission spectrum after excitation at 440 nm of buffer (black line) or peptide 12B (100 µM, purple line) 5 min
after solubilization (n= 3 independent experiments). c Th-T emission signal of buffer (black line) or peptide 12B (100 µM, purple line) at 485 nm after
excitation at 440 nm as a function of time. Data represent three independent repeats (n= 3 independent experiments). d FTIR spectrum of 100 µM peptide
12B 5min after solubilization. TEM (e) and cryo-TEM (f) of 100 µM freshly dissolved peptide 12B (both are one representative image of three independent
experiments). g Hydrodynamic radius (RH) calculated from the regularization fit of DLS data of peptide 12B (10 µM) maturation over time (dashed line=
50 nm). h Soluble fraction of peptide 12B (10 µM) determined after ultracentrifugation (250,000 × g for 30min), measured over time, and mean ± SD is
shown (n= 3 independent experiments). i Quantification of the area covered by plaques of MDCK cells treated with 10 µM peptide in a plaque-size
reduction assay with influenza A/PR8. Data are normalized to medium-treated cells and the mean ± SD is shown (n= 5 independent experiments,
statistics: one-way ANOVA with multiple comparison).
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scrambling the amino acids of the APR while maintaining its
propensity to form amyloids. As intended by their design, an
in vitro biophysical analysis showed that, in our experimental
conditions, 12Bscr2 (100 µM) organizes into amyloid-like
aggregates over time, while 12Bpro2 (100 µM) does not aggre-
gate (Supplementary Fig. 3a–f). Only at a higher concentra
tion (500 µM), peptide 12Bpro2 organizes into amorphous
aggregates (Supplementary Fig. 3d). Treatment of influenza A/
PR8-infected MDCK cells with these control peptides showed
no significant effect on viral replication, indicating that peptide
amyloid formation is necessary but in itself not sufficient for
antiviral activity (Fig. 2i, Supplementary Fig. 3g, h). Moreover,
peptide 12Bpro2 did not show inhibitory effects on influenza A
replication in the murine infection model (Fig. 1g).
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Amyloid peptide 12B interacts with influenza via PB2 in vitro.
To provide mechanistic understanding of the amyloid–virus
interaction, we used recombinant expression and purification of
the PB2 cap-binding domain of influenza A/PR8 (PB2CB), the
intended target protein of peptide 12B (Supplementary Fig. 4a),
and performed direct interaction measurements between the
synthetic amyloid 12B and the purified protein. Biolayer inter-
ferometry (BLI) showed a clear binding event of amyloid peptides
12B and 12Bscr2 to immobilized PB2CB, while 12Bpro2 did not
show any affinity for PB2CB (Fig. 3a). The dissociation constant
(Kd) of peptide 12B to PB2CB (65.8 ± 0.91 nM) is >10-fold lower
compared with 12Bscr2 (714 ± 33.9 nM) (Supplementary Fig. 4b,
c). PB2CB showed an increased binding of 8-anilinonaphtalene-1-
sulfonic acid (ANS) when seeded with amyloid peptide 12B,
indicative of a conformational change of the protein that leads to
the exposure of hydrophobic residues normally buried in the
folded protein (Fig. 3b). In agreement with the latter observation,
12B, and not control peptides 12Bpro2 and 12Bscr2, increased
Th-T binding and scattering intensity of PB2CB, consistent with
beta aggregation (Fig. 3c, d). Importantly, this increase in ANS
fluorescence, Th-T fluorescence, and scattering did not originate
from the aggregation of the peptides alone (Supplementary
Fig. 4d–f). In addition, TEM images showed that the final
structures formed by 12B-induced PB2CB aggregates are fiber-like
(Fig. 3e), compared with 12Bpro2-, 12Bscr2-, or noninduced
PB2CB aggregates, which have an amorphous structure (Supple-
mentary Fig. 4g). All together, these data show that peptide 12B
binds with nanomolar affinity to PB2CB, inducing a conforma-
tional change of the natively folded PB2CB, resulting in the for-
mation of beta-aggregates. To assess that this leads to loss of
function, we studied the so-called “cap-snatching” process, which
occurs at the initiation of viral RNA synthesis, in which PB2
binds host pre-mRNA via a 5′cap structure (m7GTP). To validate
whether specific 12B-induced aggregation is associated with a loss
of PB2 cap-binding function, we used a fluorescent polarization
assay (Supplementary Fig. 4h)23. When a fluorescently labeled
ligand (m7GTP-atto488) and purified PB2CB were mixed with
peptide 12B, a concentration-dependent loss of cap-binding
function was observed, which further decreased over time (Fig. 3f,
g; Supplementary Fig. 4i). Control peptide 12Bpro2 had no effect
on PB2 cap-binding activity, while 12Bscr2 showed only a mild
effect, possibly due to the modest affinity of this peptide to PB2CB
(Fig. 3h).
Amyloid peptide 12B interacts with influenza via PB2 in cel-
lulo. The in vitro results described in the previous section show
that amyloid peptide 12B binds to PB2, induces its aggregation,
and interferes with its function. Next, we studied whether the
same event occurs in the cellular cytoplasm. To establish that in
a cellular context the synthetic amyloid does not interfere with
viral entry in an aspecific manner, we performed a time of
addition assay. This assay shows that the antiviral activity of
12B is unchanged, whether it is used in a pretreatment setup or
added 6 h after infection (Fig. 4a, Supplementary Fig. 5a).
Moreover, when influenza A virion particles are pretreated with
amyloid peptide 12B, the antiviral activity does not change
dramatically compared with pretreatment of the cells (Fig. 4b,
Supplementary Figs. 1e and 5b). All the later indicates that 12B
does not aspecifically interfere with viral entry and suggests that
the amyloid–virus interaction occurs in the cell. To study the
interactions between amyloid peptide 12B and influenza A in
the cell and to confirm that this interaction also induces
aggregation and inactivation of PB2, we used a modified
influenza A/WSN/1933(H1N1) strain, with a FLAG-tagged PB2
(A/WSN-FLAG), facilitating PB2 detection. Immuno-
fluorescence experiments showed co-localization of a FITC-
labeled peptide 12B variant with PB2 (Fig. 4c). To support the
latter observation, we used a PEG2-biotin labeled variant of
peptide 12B, 12Bpro2, and 12Bscr2 to perform a co-
immunoprecipitation of PB2 from lysates of peptide-treated,
A/WSN-FLAG-infected MDCK cells. The enrichment of PB2 in
the co-immunoprecipitated fraction of 12B-PEG2-biotin-trea-
ted MDCK cells is consistent with a direct interaction between
amyloid peptide 12B and the target protein PB2 (Fig. 4d).
Finally, peptide 12B treatment of A/WSN-FLAG-infected
MDCK cells resulted in a reduction of soluble PB2, while the
control peptides had no effect (Fig. 4e), showing PB2 undergoes
aggregation. Taken together with the significant reduction in
viral replication upon treatment with 12B shown above (Fig. 1c,
d), these data confirm that amyloid peptide 12B interacts with
PB2 in the cytoplasm of influenza A-infected MDCK cells and
induces its inactivation through aggregation.
Amyloid peptide 12B acts in an APR-specific manner.
According to our model, the underlying properties of amyloid
interactions confer specificity upon the amyloid–virus interaction,
but it was unclear how much tolerance to sequence variation is
present. An in silico analysis of over 40,000 influenza A strains
showed that the target APR in PB2 is highly conserved (Supple-
mentary Fig. 6a). We evaluated the antiviral activity of amyloid
peptide 12B on a set of influenza A strains, across different sub-
types (H1N1, H3N2, H3N3, H3N8, H5N1), in which the fre-
quently occurring single polymorphisms of the target APR are
represented (381LIQLIVS387 to 381LVQLIVS387 or 381LFQLIVS387).
Peptide 12B retains activity against all these influenza A strains,
suggesting the interaction allows for some tolerance (Fig. 5a). In
addition, we performed an in silico mutational analysis in which
the effect of two mutations in the APR on the interaction potential
Fig. 3 Amyloid peptide 12B interacts with influenza via the PB2 target protein in vitro. a Biolayer interferometry showing association and dissociation of
10 µM peptide to his-tagged, immobilized PBCB. b, c ANS (excitation 380 nm, emission 485 nm) and Th-T (excitation 440 nm, emission 485 nm)
fluorescence of PB2CB (32 µM) with and without peptides (3.2 µM) over time. Quantification of the fluorescence signal after 15 h is shown on the right.
Data are expressed as mean ± SD (n= 3 (b) and n= 6 (c) independent experiments, statistics: one-way ANOVA with multiple comparison to PB2CB
alone). d Particle scattering (260 nm) of PB2CB (32 µM) with and without peptides (3.2 µM) over time. Quantification of scattering signal after 1 h (before
precipitation) is shown on the right. Data are expressed as mean ± SD (n= 4 independent experiments, statistics: one-way ANOVA with multiple
comparison to PB2CB alone). e TEM images of PB2CB (32 µM) with peptide 12B (3.2 µM) after 15 h incubation. f Binding of m7GTP-atto488 by PB2CB
in absence or presence (gray scale for peptide concentration) of a twofold serial dilution of peptide 12B, determined by fluorescence polarization (FP).
Mean ± SD is shown (n= 4 independent experiments). The dashed lines represent maximal binding of m7GTP-atto488 to PB2 (upper dashed line) and
free m7GTP-atto488 (lower dashed line), based on control experiments (Supplementary Fig. 4h). g Concentration-dependent effect of peptide 12B on the
binding of m7GTP-atto488 by PB2CB (5 µM) after 20 h incubation as shown by FP. Data represent normalized values (maximal binding= 100% and free
m7GTP-atto488= 0%) and mean ± SD is shown (n= 5 independent experiments). h Binding of m7GTP-atto488 by PB2CB (5 µM) with or without peptides
(7 µM) after 20 h incubation. Data represent normalized values (similar as in g) and mean ± SD is shown (n= 3 independent experiments, statistics: one-
way ANOVA with multiple comparison).
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was calculated (Supplementary Fig. 7, Supplementary Note 2).
Only 17.3% of all possible double-mutant combinations are pre-
dicted to still interact with the 381LIQLIVS387 sequence, of which
>90% would have a strong negative effect on PB2 protein stability,
and hence do not occur in natural influenza A strains. On the
other hand, 12B did not interfere with the replication of several
influenza B virus strains (B/Memphis/12/97 (B/Mem), B/Wis-
consin/01/2010 (B/Wis), and B/Brisbane/60/2008 (B/Bris)), in
which all have ~40% overall sequence homology to influenza A/
PR8 but lack the specific target APR, in vitro (Fig. 5a, b). Of note,
the corresponding target sequence in influenza B (383MEKL-
LIN389) is located in the same position in the cap-binding domain
of PB2 compared with the target sequence (381LIQLIVS387) in
influenza A PB2. In addition to the plaque-size reduction assay,
influenza B replication is also unaffected in a multicycle replica-
tion assay and 12B shows no protection against cytopathic effects
of influenza B (Supplementary Fig. 6b, c). Of note, time of addi-
tion assays and pretreatment of influenza B virion particles
showed no antiviral activity of amyloid peptide 12B, again con-
firming that our amyloid does not act as a nonspecific inhibitor of
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Fig. 4 Amyloid peptide 12B interacts with influenza via the PB2 target protein in cellulo. a Quantification of the area covered by plaques of A/PR8-
infected MDCK cells treated with 10 µM peptide 12B at different time points relative to infection. Data are normalized to medium-treated cells and mean ±
SD is shown (n= 8 from three independent experiments, statistics: one-way ANOVA with multiple comparison, p value= 0.0605). Representative images
are shown in Supplementary Fig. 5a. b Quantification of the area covered by plaques in a plaque-size reduction assay of MDCK cells infected with A/PR8
virion particles that were pretreated with peptide 12B. Concentration-dependent effect of peptide 12B is shown normalized to medium-treated virion
particles as mean ± SD (n= 3 independent experiments). Representative images are shown in Supplementary Fig. 5b. c MDCK cells treated with FITC-
labeled peptide 12B, 12Bpro2 (10 µM), or buffer for 2 h prior to A/WSN-FLAG infection (MOI= 1, 16-h infection). Cells were fixed and stained with an anti-
FLAG antibody and DAPI. One representative example of three independent experiments. dWestern blot analysis of total (input) and immunoprecipitated
fraction of MDCK cells treated with PEG2-biotin-labeled peptide (10 µM) or buffer for 2 h prior to A/WSN-FLAG infection (MOI= 1, 16-h infection).
Quantification of immunoprecipitated fraction of PB2, relative to PB2 input levels, is shown on the right. Data represent mean ± SD (n= 5 independent
experiments, statistics: one-way ANOVA with multiple comparison). Streptavidin was used as a loading control. eWestern blot analysis of PB2 distribution
in soluble and insoluble fraction of lysates of MDCK cells treated with peptide (10 µM) for 2 h prior to influenza A/WSN-FLAG infection (MOI= 1, 16-h
infection). Vimentin and GAPDH were used as loading controls for insoluble and soluble fraction, respectively. Quantification represents soluble PB2
fraction, normalized to medium-treated cells (100% soluble PB2). Data represent mean ± SD (n= 4 independent experiments, statistics: one-way ANOVA
with multiple comparison). For d and e the samples on one blot are derived from the same experiment and the gels/blots were processed in parallel. Full
blots are shown in Supplementary Fig. 12.
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viral entry (Supplementary Fig. 5a, b). Influenza B replication is
also not affected by peptide 12B in the murine infection model,
confirming the APR-specific activity in vivo (Fig. 5c). As expected
from the lack of target APR in the protein, peptide 12B showed no
effect on the aggregation or conformational stability of recombi-
nantly purified PB2CB from influenza B/Mem (PB2IBV) as seen
from Th-T and ANS binding assays (Fig. 5d, e). In the same line,
peptide 12B was not able to affect the aggregation of the highly
aggregation-prone amyloids when they share no similarity with
peptide 12B (Aβ42 or amylin (IAPP), Fig. 5f, g, respectively). To
explore the limits of the sequence-identity tolerance, we searched
for a naturally occurring aggregation-prone protein with imperfect
identity to peptide 12B. The C-terminal domain (glycosylpho-
sphatidylinositol-anchor sequence) of the prion protein (PrP)
contains a region with high sequence homology to peptide 12B,
both in human and mouse, covering only two mismatches (Q249F
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and S253G, Fig. 5h). However, peptide 12B was incapable to
convert PrP to the aggregated prion state (PrPSC) in cells
expressing soluble mouse PrPC (Fig. 5i, j). The combination of a
sequence-specific process (not affecting influenza B or PrP) that is
tolerant to single conservative substitutions (affecting the influ-
enza A variants) suggests that the approach has potential as a
broad-spectrum antiviral strategy to target influenza A.
Exploring the chemical space of antiviral synthetic amyloids. In
order to get an indication if our approach with Influenza A is
generally transferable, we set out to identify amyloids that target
the ZIKV specifically. Following the same approach as described
earlier, 63 different peptides were designed based on APRs
identified in the ZIKV proteome (African strain MR766, Sup-
plementary Table 4). Vero E6 cells were treated with peptide at a
concentration of 20 µM, 2 h prior to infection. Following infec-
tion for 48 h, the number of infected cells was determined by
immunofluorescence. Multiple peptides showed inhibitory effects
on ZIKV replication and protective effects toward the infected
mammalian cell line (Supplementary Figs. 8 and 9). Overall,
peptide R50 (RVAIAWLLRGSRVAIAWLLR), derived from an
APR identified in membrane glycoprotein M, 140VAIAWLL146,
showed the most pronounced effect compared with our positive
control compound 7-DMA (7-deaza-2′-C-methyladenosine)24. A
biophysical analysis confirmed the amyloid propensity of peptide
R50. DLS showed that peptide R50 organizes into small structures
(<50 nm) that evolve into larger aggregates (~300 µm) within 5 h
(Fig. 6a). These aggregates are positive for the amyloid-specific
dye Th-T (Fig. 6b) and have an amyloid-like morphology as seen
from TEM images (Fig. 6c). Even though peptide R50 organizes
into amyloid structures, ~80% of total peptide remains in solution
over time (Fig. 6d). A dose–response experiment, in which Vero
E6 cells were treated with different concentrations of peptide or
compound, prior to viral infection showed IC50 values of 5.25 ±
0.30 and 4.74 ± 0.31 µM for peptide R50 and 7-DMA, respectively
(Fig. 6e, f, Supplementary Fig. 10a, b). Cross-validation with
peptide 12B confirmed the APR-specificity associated with our
approach as no interference with ZIKV replication is observed
with this anti-influenza peptide (Fig. 6g, Supplementary Fig. 10c).
Importantly, the concentration-dependent inhibitory effect of
amyloid peptide R50 and 7-DMA on ZIKV replication did not
originate from aspecific toxicity on the mammalian host cell
(Fig. 6h–j). Finally, reminiscent of amyloid peptide 12B, a time of
addition assay, shows that R50 remains active, even when added
6 h after ZIKV infection (Supplementary Fig. 11a, b).
From these data it appears that our design approach is
generally applicable and can be used to specifically target different
viruses. In other words, these family of antiviral peptides
constitutes a novel chemical space that could be mined for novel
antivirals that act through the mechanism of targeted protein
aggregation.
Discussion
Human encoded amyloids possess functional roles and are not
just pathogenic byproducts in disease1. The AD-associated
amyloid, Aβ, physically interacts with herpes virus particles and
interferes with viral replication. Building on this observation, we
present here the reverse engineering of synthetic amyloids that
specifically interact with a predefined target virus and reduce viral
replication. Since it is well established that amyloid interactions
are driven by the sequence-specific assembly of homologous
aggregation-prone fragments8–12, we designed our amyloids by
encoding a unique amino acid fragment corresponding to a viral
APR. Using influenza A as a model virus, we designed an amyloid
with a homologous APR to the PB2 protein. Our results show
that this homologous APR drives the interaction between the
amyloid and PB2, leading to aggregation and loss-of-function of
the PB2 protein. We show that our amyloid does not aspecifically
interfere with virus entry, instead amyloid–virus interaction
occurs in the cytosol of the infected cell. Following amyloid
uptake25, a sequence-specific binding event induces PB2 aggre-
gation in the cytosol. Since APRs are usually buried inside the
core of the folded protein, we suspect that this interaction hap-
pens during protein translation15, when the APR might still be
solvent exposed. PB2 loses its essential cap-snatching function
following the amyloid-induced aggregation, leading to reduced
viral replication. Importantly, our amyloid interacts with PB2 in a
sequence-specific manner, since two mutations are sufficient to
abrogate the interaction. Finally, the universal mechanism
underlying homotypic APR interactions allowed us to extrapolate
this technology resulting in a second amyloid that inhibits ZIKV
replication.
Aβ encodes an APR matching an APR in envelope glycopro-
tein B, a herpes protein4. Our results indicate that such homolog
APRs are sufficient to drive the amyloid–virus interaction and
provide a mechanistic understanding how such interactions
would arise. Whether the suggested mechanism of interaction is
broadly used for amyloid–virus interactions like the Aβ amyloid
and the herpes glycoprotein B remains to be determined together
with the general role of amyloids in innate immunity. However,
our work demonstrates that the increasing understanding of the
functional aspects of amyloids could extend beyond purely
amyloid-specific structural roles such as scaffolding or con-
formational switches1,26–28. Instead, amyloid structures also
entail the ability to engage in very specific interactions with other
proteins under complex physiological conditions and affect their
Fig. 5 Amyloid peptide 12B acts as a sequence-specific interferor of influenza A. a Quantification of area covered by plaques of influenza-infected MDCK
cells, treated with 10 µM peptide 12B. Data are normalized to buffer-treated cells and mean ± SD is shown (n= 4 independent experiments, statistics: two-
sided one-sample t-test). A list of abbreviations is provided in “Methods.” b Local alignment of PB2 from influenza A/PR8 and B/Mem. Target APRs are
highlighted in red (A/PR8) and blue (B/Mem). c Viral load in the lungs of influenza B/Mem-infected mice after daily injections of buffer, 2.5 mg/kg peptide
12B, 2.5 mg/kg peptide 12Bpro2 (i.v.); or 25 mg/kg Tamiflu (oral gavage) for 6 days. Data represent mean ± SD (n= 13 mice, five independent experiments,
statistics: one-way ANOVA with multiple comparison, p value= 0.6027). d, e Th-T and ANS fluorescence of PB2CB(IBV) (32 µM) without and with
peptides (3.2 µM, enlarged in the inserts). Fluorescence after 20 h is shown on the right as mean ± SD (n= 3 independent experiments, statistics: one-way
ANOVA with multiple comparison, p value= 0.4218 for d and 0.1499 for e). f, g Th-T fluorescence of amyloid beta (10 µM) and IAPP (10 µM) without and
with peptide 12B (1 µM) is shown. Self-seeded control is included by using preformed aggregates of amyloid beta and IAPP, respectively (1 µM). Th-T
fluorescence at plateau is shown on the right as mean ± SD (n= 4 independent experiments, statistics: one-way ANOVA with multiple comparison).
h Local alignment of the target APR in peptide 12B with human prion protein (PrPhuman). Western blot analysis of proteinase K-treated lysates of L929 15.9
cells (six passages, (i)) and CAD5 cells (eight passages, (j)) post treatment with peptides (1 or 10 µM) with or without Lipofectamine 2000 (LF). As
controls, cells were exposed to brain homogenate from a terminally diseased mouse infected with scrapie strain 22L (PrPSc) or with normal (Mock) brain
homogenate. GAPDH was used as loading control. The samples are derived from the same experiment and the gels/blots were processed in parallel. Full
blots are shown in Supplementary Fig. 12.
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biological function. Finally, the ability to reverse engineer syn-
thetic amyloids with specific biological activity also offers a new
toolkit for protein functional interference and possibly ther-
apeutic intervention.
Methods
Reagents. All reagents and antibodies are listed in Supplementary Table 5.
Mouse models. All mouse experiments were conducted according to the National
(Belgian Law 14/08/1986 and 22/12/2003, Belgian Royal Decree 06/04/2010) and
European (EU Directives 2010/63/EU, 86/609/EEG) animal regulations. All pro-
tocols were approved by the Institutional Ethics Committee of Ghent University
(Eth. Com. no. 2018-010). Five to eight weeks old healthy female wild-type BALB/
C mice were used in all mice experiments. Three or four mice were housed together
in standardized cages with unrestricted access to food and water.
Tissue culture. MDCK cells were obtained from the American Type Culture
Collection (ATCC). MDCK cells were maintained at 37 °C with 5% CO2 in DMEM
medium (GIBCO), supplemented with 10% FCS (GIBCO), L-glutamine (GIBCO),
and nonessential amino acids (GIBCO). HEK 293T cells were obtained from the
ATCC and maintained in DMEM medium, supplemented with 10% FBS, 1 mM
sodium pyruvate, and nonessential amino acids. Mouse fibroblast cell line L929
(ECACC; L929 (NCTC); #85103115) was purchased from Sigma-Aldrich (Tauf-
kirchen, Germany). The L929 subclone 15.9, which is highly susceptible to the
mouse-adapted scrapie strain 22L, was used for all experiments29,30. CAD5 cells31
were a kind gift of Corinne Lasmezas (The Scripps Research Institute, FL).
Bioinformatics. The statistical thermodynamics algorithm, TANGO, was used for
all APR identifications. A cutoff on the TANGO score of five per residue was
selected, which results in a Matthews correlation coefficient between prediction and
experiment of 0.92. Settings within TANGO: temperature= 298 K; pH= 7.5; ionic
strength= 0.15 M; and minimum length of APRs= 5.
Viruses. Viruses used throughout the work include A/Puerto Rico/8/34 (H1N1):
A/PR8, A/NIBRG-14 (H5N1): A/NIB, A/Swine Ontario/42729A/2001 (H3N3): A/
SwO, A/Udorn/307/72 (H3N2): A/Udor, A/Chicken/Nanchang/3-120/2001
(H3N2): A/Chic, A/Duck/Ukraine/1/63 (H3N8): A/Duck, A/WSN-FLAG (H1N1):
A/WSN(F), B/Memphis/12/97 (Yamagata-lineage): B/Mem, B/Wisconsin/01/2010
(Yamagata-lineage): B/Wis, and B/Brisbane/60/2008 (Victoria-lineage): B/Bris. A/
NIBRG is an influenza stain derived from a highly pathogenic H5N1 strain (A/
Vietnam/1194/2004), in which the HA is adapted to a low-pathogenic form. Only
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Fig. 6 Peptide R50 organizes into amyloid structures and interferes with ZIKV replication. a Hydrodynamic radius (RH) calculated from the
regularization fit of DLS data of peptide R50 (10 µM) maturation over time. b Th-T emission signal of 10 µM peptide R50 at 485 nm after excitation at 440
nm as a function of time (n= 3 independent experiments). c TEM image of 10 µM peptide R50 after 6 h incubation. d Soluble fraction of peptide R50 (10
µM) determined after ultracentrifugation (250,000 × g for 30min), measured over time, and mean ± SD is shown (n= 3 independent experiments). Dose-
dependent effect of 7-DMA (e), peptide R50 (f), and peptide 12B (g) on the fraction of ZIKV-infected cells following 48 h of infection with a MOI of 0.1.
Data are normalized to DMSO-treated, infected cells (100% infected cells) and mean values ± SD are shown (n= 3 independent experiments).
Representative images are shown in Supplementary Fig. 10. Dose-dependent effect of 7-DMA (h), peptide R50 (i), and peptide 12B (j) on cell viability
of Vero E6 cells without ZIKV infection. Data are normalized to DMSO-treated, noninfected cells (100% cell viability) and the mean values ± SD are shown
(n= 3 independent experiments).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16721-8
10 NATURE COMMUNICATIONS |         (2020) 11:2832 | https://doi.org/10.1038/s41467-020-16721-8 | www.nature.com/naturecommunications
HA and NA are derived from the pathogenic strain, the other genes are derived
from A/PR8. A/WSN-Flag, a recombinant version of A/WSN/1933 (H1N1) car-
rying a Flag-tagged PB2 protein, was a kind gift of Nadia Naffakh. All viruses were
propagated on MDCK cells. All influenza virus stocks were grown in specific-
pathogen free eggs, harvested and purified.
Cell viability assay. All peptide treatments were done in DMEM medium without
serum. Toxicity of the peptide treatments was evaluated using the CellTiter-Blue
Cell Viability Assay according to the instructions of the manufacturer (Promega,
USA). Briefly, cells were seeded to ~20,000 cells per well in a 96-well plate and
allowed to attach overnight. Peptides were diluted in cell medium without serum
(concentration indicated in the corresponding figure) and cells were treated for
~24 h, unless stated otherwise. Twenty microliters of the CellTiter-Blue reagent was
added to each well and the plate was incubated for 1 h. Finally, fluorescence was
measured at 590 nm by exciting at 560 nm with a ClarioStar plate reader (BMG
Labtech, Germany).
Plaque-size reduction assay. MDCK cells were seeded in complete DMEM
medium in 24-well format (160,000 cells per well) and allowed to attach overnight.
Cells were washed once with serum-free DMEM medium, treated with peptide (10
µM, unless stated otherwise), and infected with virus (25 pfu, unless stated
otherwise) 2 h later. Two hours after infection, all the remaining peptide and virus
were washed away with DMEM medium and an overlay of 0.6% avicel32 in serum-
free DMEM medium supplemented with 2 µg/mL TPCK-treated trypsin was
added. Virus was allowed to replicate and 48–72 h later cells were fixed and stained
for ribonucleoprotein (RNP) using goat anti-RNP (BEI Resources, NR-3133) for
influenza A virus or convalescent murine serum for influenza B virus. After
staining with anti-goat-HRP (Santa Cruz Biotechnology) or anti-mouse-HRP (GE
Healthcare), plaques were visualized using True-Blue HRP substrate (SeraCare).
Quantification of the area covered by the plaques was performed by the “colony
area” plug-in in ImageJ.
Hemolytic assay. Fresh blood was pooled from healthy volunteers (Red Cross
Flanders) and erythrocytes were collected by centrifugation 1000 × g for 5 min.
EDTA was added as an anticoagulant. The cell pellet was washed three times with
phosphate-buffered saline (PBS) and diluted to a concentration of 8% in PBS. One
hundred microliters of 8% red blood cells solution was mixed with 100 µL of serial
dilutions of peptides in PBS buffer in 96-well plates (BD Biosciences). The reaction
mixtures were incubated for 1 h at 37 °C, centrifuged for 10 min at 1000 × g, and
100 µL of supernatant was transferred to a sterilized 96-well plate (BD Biosciences,
flat bottom). The release of hemoglobin was determined by measuring the absor-
bance of the supernatant at 495 nm. Erythrocytes in 1% Triton and maximum used
concentration of buffer were used as the control of 100% and 0% hemolysis,
respectively.
Biophysical characterization. A DynaPro DLS plate reader instrument (Wyatt,
Santa Barbara, CA, USA) equipped with an 830 nm laser source was used to
determine the hydrodynamic radius (RH) of the peptide particles. Two hundred
microliters of each sample (at 100 or 10 µM, unless stated otherwise) was placed
into a flat-bottom 96-well microclear plate (Greiner, Frickenhausen, Germany).
The autocorrelation of scattered light intensity at a 32° angle was recorded for 5 s
and averaged over 20 recordings to obtain a single data point. The Wyatt Dynamics
v7.1 software was used to calculate the hydrodynamic radius by assuming linear
particles. The amyloid-specific dye Th-T was used to study the aggregation state of
peptides. Two hundred microliters of each peptide sample (at 100, unless stated
otherwise) was placed into a flat-bottom 96-well microclear plate (Greiner,
Frickenhausen, Germany) and the dye was added to a final concentration of 25 µM.
A ClarioStar plate reader (BMG Labtech, Germany) was used to measure fluor-
escence by exciting the samples at 440–10 nm and fluorescence emission was
observed at 480–10 nm (or a complete spectrum ranging from 470–600 nm).
Aggregation kinetics were obtained by placing 200 µL of the peptide solution with a
final concentration of 25 µM Th-T into a flat-bottom 96-well microclear plate.
Fluorescence emission was monitored at 480–10 nm after excitation at 440–10 nm.
Every 5 min Th-T fluorescence was measured. FTIR spectroscopy was performed
using a Bruker Tensor 27 infrared spectrophotometer (Bruker, Germany) equipped
with a Bio-ATR II accessory (Harrick Scientific Products, USA). Spectra were
recorded in the range of 1000–3500 cm−1 at a spectral resolution of 2 cm−1 by
accumulating 256 data acquisitions. The spectrophotometer was continuously
purged with dried air. Spectra were corrected for atmospheric water vapor inter-
ference, baseline-subtracted, and vector normalized in the amide II area
(1500–1600 cm−1) as implemented in OPUS software (Bruker). All measurements
were performed with 30 µL peptide (at 100, unless stated otherwise) and at room
temperature. Solubility of the peptides was quantified by determining the super-
natant concentration following ultracentrifugation (250,000 × g for 30 min).
Transmission electron microscopy. Formvar film coated 400-mesh copper grids
(Agar Scientific Ltd., England) were first glow-discharged to improve adsorption
efficiency. Next, 10 µL of each sample was adsorbed for 5 min and afterward the
grids were washed by contact with three drops of ultrapure water. Finally, negative
staining was performed by contact with one drop of uranyl acetate (2% w/v) for 1
min. The grids were examined using a JEM-1400 transmission electron microscope
(JEOL, Japan) at accelerating voltage 80 keV.
Cryo-electron microscopy. 3.5 μL of sample was applied to a 300-mesh quantifoil
grid and incubated for 30 s. Next, grids were mounted in a plunge freezer (EMBL),
blotted one-sided for 3 s using a Whatman 1 filter paper, and plunged into liquid
ethane at a temperature of −180 °C, and stored in liquid nitrogen until observation
in the electron microscope. The samples were transferred to a Gatan 914 cryo-
holder and imaged at low-dose conditions at −177 °C, using a JEOL JEM-1400
TEM equipped with an 11 Mpxl Olympus SIS Quemesa camera.
Aβ 42 and amylin preparation. The lyophilized Aβ42, Aβ42-HiLyte647, and
amylin peptide were purchased from rPeptide (A-1163-1), AnaSpec (AS-64161),
and EuroGenTec (AS-60804), respectively, and its suspension and monomeric
sample isolation was preformed accordantly with a standard procedure previously
described by our group33. Briefly, each vial content was suspended in 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP), evaporated under a nitrogen stream, and solubi-
lized in DMSO to a final concentration of 1 mg/mL. DMSO was removed using a 5-
mL HiTrap desalting column (GE Healthcare), where the peptide was eluted in 10
mM Tris (pH 7.5) buffer. The concentration of the final monomeric sample was
quantified by nanodrop (at 280 nm). The peptide was immediately diluted to 25
µM using the same Tris buffer, and further diluted in the required concentration
for the next assays.
Binding studies. Binding of peptides to recombinant PB2CB was determined with
BLI by using an Octet RED96 instrument (ForteBio, Pall Life Sciences) at 25 °C.
His-tagged PB2CB was captured on a nickel-coated (Ni-NTA) biosensor (ForteBio,
Pall Life Sciences) in a 50 mM Tris buffer (pH 8.0 and 200 mM NaCl) for 300 s.
After three washing steps in peptide buffer (50 mM Tris pH 8.0; 20 mM guanidine
thiocyanate), association and dissociation of the peptides to his-tagged PB2CB was
measured for 200 and 550 s, respectively. Biosensors without PB2CB were used to
control for aspecific binding of peptides to the sensor (data shown are corrected for
aspecific binding). Dissociation constant (Kd) values were calculated using the Data
Analysis software (Octet Software 9.0) by fitting the data to a 1:1 binding model.
Seeding assay. All seeding experiments were performed by mixing freshly purified
PB2 protein (32 µM, unless stated otherwise) with 10% molar ratio freshly dis-
solved peptide. For ANS measurements, 25 µM of the dye was added to this
mixture and fluorescence was recorded by exciting at 380–10 nm and monitoring
emission at 480–10 nm. For Th-T measurements, 25 µM of the dye was added to
the peptide–protein mixture and fluorescence was recorded by exciting at 440 nm
and monitoring emission at 480 nm. Light scattering at 266 nm was monitored
with the Optim1000 (Unchained Labs) by using a 266 nm laser.
Cap-binding assay. Cap-binding activity of PB2CB was checked by incubation of
20 nM m7GTP-Atto488 with different concentration of purified PB2CB-IAV.
Fluorescent polarization of the substrate (m7GTP-Atto488) was measured with a
PolarStar Optima plate reader using 485–10 nm excitation and 520–10 nm emis-
sion filters (BMG Labtech, Germany). Different concentrations of peptides were
added to this m7GTP-Atto488-PB2CB mixture (5 µM of PB2CB) and the effect on
polarization was measured. These data points were always compared with the effect
of peptide alone on polarization of m7GTP-Atto488.
PB2 solubility. MDCK cells were plated at a density of 300,000 cells/well in a six-
well plate 1 day before the experiment. Cells were treated with 10 µM peptide and
infected with virus (A/WSN-FLAG, MOI= 1). After 16 h, cells were lysed with
NP-40 buffer, supplemented with Complete protease inhibitor (Roche), for 30 min
on ice. Cell lysates were centrifuged (20,000 × g) for 20 min at 4 °C and the
supernatant was isolated as “soluble fraction.” The pellet was washed 3× with PBS
and finally dissolved in 30 µL 8M urea for 1 h (“insoluble fraction”). All samples
were heated to 95 °C in SDS-PAGE loading buffer (2% SDS) for 10 min. The
samples were separated by SDS-PAGE and anti-FLAG antibody (anti-FLAG, Cell
Signaling D6W5, 1:1000) was used to detect PB2. All blots were also stained with
an anti-vimentin antibody (anti-Vimentin, Santa Cruz V9, 1:5000), as a control for
insoluble fraction, and an anti-GAPDH antibody (anti-GAPDH, Santa Cruz 6C5,
1:1000), as a control for soluble fraction.
PB2 co-immunoprecipitation. MDCK cells were plated, infected with A/WSN-
FLAG, treated with peptide, and lysed exactly as described in the previous para-
graph. Lysates were then mixed with streptavidin-coated beads (Dynabeads™ M-
280 Streptavidin, Thermo Fisher Scientific) and rotated for 1 h at 4 °C. The beads
were subsequently washed three times for 10 min with NP-40 buffer supplemented
with 0.1% Triton. In all steps, 1% BSA was included to reduce aspecific binding to
the beads. After washing, the beads were heated to 95 °C in SDS-PAGE loading
buffer (2% SDS) for 10 min before SDS-PAGE. An anti-FLAG antibody (anti-
FLAG, Cell Signaling D6W5, 1:1000) was used to detect PB2 and the fraction that
was bound to the streptavidin-coated beads was always compared with amount of
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PB2 present in the total lysate (“input”). Streptavidin monomers were used a
loading control for the immunoprecipitated fraction.
Immunofluorescence. MDCK cells were plated at a density of 30,000 cells/well in
an eight chamber coverslide (155409, Lab-Tek II, Nunc) 1 day before the experi-
ment. Cells were treated with 10 µM FITC-labeled peptide for 2 h and infected with
A/WSN-FLAG (MOI= 1). After 16 h, cells were washed with PBS and fixed by
incubation with 4% paraformaldehyde for 30 min. Next, cells were blocked and
permeabilized with blocking buffer (PBS containing 1% BSA and 0.2% Triton X-
100) and incubated with primary antibody (anti-FLAG, Cell Signaling D6W5,
1:250) for 1 h. After washing with PBS, cells were incubated with goat anti-rabbit
antibody conjugated to AlexaFluor-594 for 1 h (Thermo Fisher scientific, 1:2000 in
blocking buffer). After two washing steps, cells were mounted with DAPI-
containing mounting medium (ProLong Gold Antifade with DAPI, Thermo Fisher
scientific). Confocal images were taken using a Leica SP8 DMI8 with a HC PL APO
CS2 63×/1.40 OIL objective using a HyD detector. Images were taken in uni-
directional scanning mode with a line averaging of 4 and a frame averaging of 2
and a maximum laser power of 2%. Samples were visualized using a 405-diode and
OPSL 488 and OPSL 552 lasers. Images were deconvolved with Huygens Suite
version 16.10 (Scientific Volume Imaging, The Netherlands) with best resolution
settings and adjusted for the used mounting medium (Prolong Gold, Thermo
Fisher Scientific) in the LASX software. Images were cropped in Adobe Photoshop
and aligned using Adobe Illustrator.
In vitro cross-seeding experiments. Aβ (1–42) or amylin (IAPP) were prepared
as described above. For every cross-seeding experiment, 10 µM of the aggregating
protein was mixed with 10% molar ratio of the peptide or preaggregated protein
and 25 µM Th-T was added. This was performed in a final volume of 100 µL in
Costar 3880 plates (black, nontreated, half area with transparent bottom, Corning),
sealed with a transparent film. The aggregation kinetics were monitored by Th-T
fluorescence at 480 nm after excitation at 440 nm. Data points were recorded every
5 min for a total time of 10 h. These experiments were all done at room
temperature.
Peptide transfection (prion seeding). For exposure of cells to peptides, L929 15.9
and CAD5 cells were seeded 1 day before transfection at a density of 30,000 cells
per well in 24-well plates. The next day, cells were exposed to 10 or 1 µM peptides
mixed with or without 1 µL Lipofectamine 2000 in 200 µL OptiMEM medium
without FCS and antibiotics for 5 h. Subsequently, 300 µL growth medium was
added. Cells were incubated with peptides for 3 days and confluent cell monolayers
were expanded and passaged until passage 8. Cells passages 6–8 were tested for
PrPSc and PrPC content. Ten percent scrapie brain homogenates (22L, positive
control) and uninfected brain homogenates (Mock, negative control) were pre-
pared in OptiMEM using a Dounce homogenizer (Homogenisator potter S, Sar-
torius, Goettingen, Germany). Debris was pelleted (870 × g, 5 min, 4 °C) and
supernatant was stored at −80 °C. Cells in 24-well plates were exposed to 1% v/v
brain homogenate (in OptiMEM/10% FCS) from Mock mice or mice terminally
sick upon infection with mouse-adapted prion strain 22L for 5 h, then the brain
homogenate was diluted 1:3 with growth medium. The next day the brain
homogenate was discarded and cells were subsequently cultured in medium
without brain homogenate. Confluent cell monolayers were expanded and passaged
up to eight times. Cells passages 6 and 8 were tested for PrPSc and PrPC content.
Western blot analysis and proteinase K (PK) treatment. For PrPSc detection,
cells were lysed in lysis buffer (100 mM NaCl, 10 mM Tris/HCl pH 7.5, 10 mM
EDTA, 0.5% Triton X-100, 0.5% desoxycholate acid sodium salt) and lysates were
digested with 20 µg/mL (PK) at 37 °C for 30 min. Proteolysis was stopped by
adding 0.5 mM Pefabloc (Roche). The samples were then precipitated with
methanol at −20 °C and PrPSc was detected by immunoblot using anti-PrP anti-
body 4H11. For detection of total PrP (PrPC and PrPSc) and GAPDH, lysate
aliquots were supplemented with 0.5 mM Pefabloc and precipitated with methanol.
Aliquots were analyzed on NuPAGE®Novex® 4–12% Bis-Tris Protein Gels (Life
Technologies) followed by transfer onto a PVDF membrane (GE Healthcare) in a
wet blotting chamber overnight at 4 °C. PrPC blots were stripped with Re-blot
solution (Merck Millipore, Darmstadt, Germany) and re-probed with an antibody
directed against GAPDH ab8245 (1:1000; Abcam).
In vivo efficacy study. Female 7–8-week-old BALB/c mice were purchased from
Charles River (Italy) and housed in individually ventilated cages under specific-
pathogen-free conditions in a temperature-controlled biosafety level 2 room with 14/
10-h light/dark cycles. All mouse experiments were conducted according to the
National (Belgian Law 14/08/1986 and 22/12/2003, Belgian Royal Decree 06/04/2010)
and European (EU Directives 2010/63/EU, 86/609/EEG) animal regulations. All
protocols were approved by the Institutional Ethics Committee of Ghent University
(Eth. Com. no. 2018-010). To assess the in vivo antiviral activity of selected peptides
and controls, mice were treated i.v. with 100 µL of peptide solution (2.5mg/kg) 4 h
after infection and every 24 h thereafter. Infection was done intranasally under
ketamine/xylazine sedation by instilling 50 µL of mouse-adapted A/PR8 or B/Mem
(2x LD50) in PBS in both nostrils. Six days after infection/treatments, mice were
euthanized and lungs were aseptically removed for titration of pulmonary virus titers.
For this, lungs were homogenized in 1mL PBS using metal beads and the Qiagen
TissueLyser II. Cell debris was removed by centrifugation and virus titers were
determined by titrating serial dilutions in plaque assay.
Supplementary methods. Supportive methods such as protein synthesis, peptide
synthesis, antiviral assays, and peptide radio-labeling experiments are described
in Supplementary Methods.
Statistics and reproducibility. Statistical analysis was performed using Prism
(Graphpad Version 7.0) or R-studio (Version 1.1.456). Sample sizes (n) of animals
or number of biological repeats of experiments are indicated in the specific figures.
Unpaired Student’s t test, one-sample t test, and ANOVA were used to determine
significant differences between samples unless otherwise indicated. Significance
levels: *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001. Nonsignificant
differences (P > 0.05) are not separately labeled, unless stated otherwise. Micro-
graphs, confocal images, and western blots were all repeated as four independent
experiments, except for Fig. 5d, which was repeated in five independent experi-
ments. One representative image is shown in the manuscript.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All available PB2 sequences of influenza A were retrieved from fludb.org (https://www.
fludb.org/brc/influenza_sequence_search_protein_display.spg?method=ShowCleanSearch&
decorator=influenza). The datasets generated during and/or analyzed during the current
study are available from the corresponding author on reasonable request.
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